Skip to main content

Grafa News and Videos — Page 1461

Latest

Grafa

FDA grants priority review to Merck’s Keytruda combo for muscle-invasive bladder cancer

Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted priority review for two supplemental Biologics License Applications (sBLA) involving its anti-PD-1 therapy, Keytruda.

Read more: FDA grants priority review to Merck’s Keytruda combo for muscle-invasive bladder cancer

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift